## MEDP: Medpace Holdings, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -6.6% below STRENGTH zone (3.0-6.0%); PEG 4.14 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($512.35)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. WINTON GROUP Ltd Sells 5,478 Shares of Medpace Holdings, Inc. $MEDP**
- Source: MarketBeat | 20251208T141013 | Neutral | Relevance: 99%
-  WINTON GROUP Ltd decreased its stake in Medpace Holdings, Inc. by 27.5% by selling 5,478 shares, retaining 14,476 shares valued at approximately $4.54 million. This move comes as Medpace reported strong quarterly earnings, beating analyst expectations, and provided optimistic full-year 2025 EPS guidance, yet insiders continue to sell a significant amount of shares. Analysts currently maintain a "Hold" rating for the stock, with an average target price below its current trading price.

**2. Epoch Investment Partners Inc. Raises Holdings in Medpace Holdings, Inc. $MEDP**
- Source: MarketBeat | 20251206T043337 | Neutral | Relevance: 98%
-  Epoch Investment Partners Inc. increased its stake in Medpace Holdings, Inc. by 11.4%, now holding 445,231 shares valued at approximately $139.74 million. This accumulation comes despite significant insider selling totaling $233.39 million by executives within the last 90 days. Medpace (NASDAQ:MEDP) reported strong quarterly earnings, beating EPS estimates and demonstrating 23.7% year-over-year revenue growth, but analysts maintain a "Hold" rating due to its high valuation.

**3. XTX Topco Ltd Sells 5,327 Shares of Medpace Holdings, Inc. $MEDP**
- Source: MarketBeat | 20251208T130949 | Neutral | Relevance: 98%
- XTX Topco Ltd significantly reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 84.1% in Q2, selling 5,327 shares and retaining 1,009 shares. While institutional investors like Invesco, Mawer, and JPMorgan increased their holdings, company insiders, including CEO August J. Troendle and VP Susan E. Burwig, sold a substantial number of shares, totaling 387,925 shares valued at $233.4 million over the past 90 days. The stock currently has a "Hold" consensus rating from analysts with an average target price of $487.18.

**4. Arrowstreet Capital Limited Partnership Grows Position in Medpace Holdings, Inc. $MEDP**
- Source: MarketBeat | 20251207T083337 | Neutral | Relevance: 98%
- Arrowstreet Capital Limited Partnership increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 25.8% in Q2, acquiring an additional 21,040 shares, bringing their total to 102,739 shares valued at $32.25 million. This increase comes despite recent insider selling by the CEO and CFO, who collectively sold shares worth over $2 million, though insiders still retain a 20.30% ownership. Medpace recently surpassed quarterly earnings and revenue estimates, prompting some analysts, like Mizuho, to raise their price targets, maintaining a consensus "Hold" rating with an average target of $487.18.

**5. Jump Financial LLC Takes $15.73 Million Position in Medpace Holdings, Inc. $MEDP**
- Source: MarketBeat | 20251208T120949 | Somewhat-Bullish | Relevance: 98%
-  Jump Financial LLC has acquired a new position of 50,114 shares, valued at approximately $15.73 million, in Medpace Holdings, Inc. Several other hedge funds have also increased their holdings in Medpace, indicating continued institutional interest. Despite a "Hold" average rating, the company recently topped earnings estimates and has a consensus price target of $487.18.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | BMO Capital | $600 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | BMO Capital | init | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($4.35M) |
| Sells | 27 ($204.69M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 8.4% (-4.4%)
- Vanguard Group Inc: 8.1% (-4.5%)
- AQR Capital Manageme: 3.6% (+65.1%)
- Wasatch Advisors LP: 3.3% (-2.1%)
- State Street Corpora: 2.4% (-4.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.1% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $205M sold (27 transactions in 90 days).
3. Valuation stretched: PEG 4.1x requires aggressive growth execution.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.14 signals overvaluation risk, limited margin of safety. Forward P/E 33.3x stretched relative to 9% growth. Quality metrics strong (ROE 74%, ROA 16%, margin 18%). Insider selling cluster ($204.7M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $15.5B |
| Beta | 1.43 |
| 52W Range | $250.05 - $626.25 |
| Short Interest | 6.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.14 |
| Forward P/E | 33.3 |
| Current P/E | 36.3 |
| YoY Growth | 9.1% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from -4.5% to -6.6% (-2.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.6pp (needs >3.0% for momentum thesis). Underperforming sector by 3.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.33x) but short-term weakness (below SMA20). MACD histogram bearish (-8.30), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -6.56% (CS: 2) | Weak |
| RSI_14 | 37.1 | Neutral |
| MACD Histogram | -8.30 | Bearish |
| vs SMA20 | 0.935x | Below |
| vs SMA50 | 0.969x | Below |
| vs SMA200 | 1.334x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $549.17
- **Stop Loss:** $512.35 (6.7% risk)
- **Target:** $585.99 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 13
- **Position Value:** $7,139.21
- **Portfolio %:** 7.14%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-09 (Est: $4.21)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.57 | $3.86 | +8.1% |
| 2025Q2 | $3.00 | $3.10 | +3.5% |
| 2025Q1 | $3.07 | $3.67 | +19.6% |
| 2024Q4 | $3.12 | $3.68 | +18.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*